Daniel Umbricht

Daniel Umbricht

UNVERIFIED PROFILE

Are you Daniel Umbricht?   Register this Author

Register author
Daniel Umbricht

Daniel Umbricht

Publications by authors named "Daniel Umbricht"

Are you Daniel Umbricht?   Register this Author

50Publications

867Reads

39Profile Views

Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis.

Schizophr Bull 2019 01;45(1):57-68

Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, CIBERSAM. Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbx192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293224PMC
January 2019

In Search of Biomarkers for Autism Spectrum Disorder.

Autism Res 2018 11 15;11(11):1567-1579. Epub 2018 Oct 15.

Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development NORD, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/aur.2026
Publisher Site
http://dx.doi.org/10.1002/aur.2026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282609PMC
November 2018

Nailing the Right Dose! The Key for Developing Glycine Transporter Inhibitors for Schizophrenia.

Authors:
Daniel Umbricht

Biol Psychiatry 2018 09;84(6):394-395

Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopsych.2018.07.006DOI Listing
September 2018

Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient.

Chimia (Aarau) 2018 Aug;72(7):477-484

Roche Pharmaceutical Research and Early Development (pRED) Roche Innovation Center Basel Medicinal Chemistry Department 124 Grenzacherstrasse, B 92 /6.30 CH-4070 Basel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2533/chimia.2018.477DOI Listing
August 2018

Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient.

Chimia (Aarau) 2018 Aug;72(7):477-484

Roche Pharmaceutical Research and Early Development (pRED) Roche Innovation Center Basel Medicinal Chemistry Department 124 Grenzacherstrasse, B 92 /6.30 CH-4070 Basel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2533/chimia.2018.477DOI Listing
August 2018

An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype.

Authors:
Nese Direk Stephanie Williams Jennifer A Smith Stephan Ripke Tracy Air Azmeraw T Amare Najaf Amin Bernhard T Baune David A Bennett Douglas H R Blackwood Dorret Boomsma Gerome Breen Henriette N Buttenschøn Enda M Byrne Anders D Børglum Enrique Castelao Sven Cichon Toni-Kim Clarke Marilyn C Cornelis Udo Dannlowski Philip L De Jager Ayse Demirkan Enrico Domenici Cornelia M van Duijn Erin C Dunn Johan G Eriksson Tonu Esko Jessica D Faul Luigi Ferrucci Myriam Fornage Eco de Geus Michael Gill Scott D Gordon Hans Jörgen Grabe Gerard van Grootheest Steven P Hamilton Catharina A Hartman Andrew C Heath Karin Hek Albert Hofman Georg Homuth Carsten Horn Jouke Jan Hottenga Sharon L R Kardia Stefan Kloiber Karestan Koenen Zoltán Kutalik Karl-Heinz Ladwig Jari Lahti Douglas F Levinson Cathryn M Lewis Glyn Lewis Qingqin S Li David J Llewellyn Susanne Lucae Kathryn L Lunetta Donald J MacIntyre Pamela Madden Nicholas G Martin Andrew M McIntosh Andres Metspalu Yuri Milaneschi Grant W Montgomery Ole Mors Thomas H Mosley Joanne M Murabito Bertram Müller-Myhsok Markus M Nöthen Dale R Nyholt Michael C O'Donovan Brenda W Penninx Michele L Pergadia Roy Perlis James B Potash Martin Preisig Shaun M Purcell Jorge A Quiroz Katri Räikkönen John P Rice Marcella Rietschel Margarita Rivera Thomas G Schulze Jianxin Shi Stanley Shyn Grant C Sinnamon Johannes H Smit Jordan W Smoller Harold Snieder Toshiko Tanaka Katherine E Tansey Alexander Teumer Rudolf Uher Daniel Umbricht Sandra Van der Auwera Erin B Ware David R Weir Myrna M Weissman Gonneke Willemsen Jingyun Yang Wei Zhao Henning Tiemeier Patrick F Sullivan

Biol Psychiatry 2017 09 8;82(5):322-329. Epub 2016 Dec 8.

Department of Psychiatry, Genomic Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Center for Psychiatric Genomics, Genomic Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopsych.2016.11.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462867PMC
September 2017

Placebo Response and Practice Effects in Schizophrenia Cognition Trials.

JAMA Psychiatry 2017 08;74(8):807-814

Neuroscience, Ophthalmology, Rare Diseases, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamapsychiatry.2017.1574DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710557PMC
August 2017

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Am J Psychiatry 2017 Mar 6;174(3):216-229. Epub 2016 Dec 6.

From King's College London, Institute of Psychiatry, Psychology, and Neuroscience; MRC Clinical Sciences Centre; Institute of Clinical Sciences, Imperial College, and Hammersmith Hospital London; the Department of Psychiatry, University of Toronto, and the Centre for Addiction and Mental Health, Toronto; the Section of Psychiatry and Treatment Resistant Psychosis and the Laboratory of Translational Psychiatry, School of Medicine of Naples Federico II, Naples; the Departments of Psychiatry and Neuroscience, Erasmus Medical Center, and Antes Mental Health Care, Rotterdam, the Netherlands; the Feinstein Institute for Medical Research, Psychiatry Research, Zucker Hillside Hospital, Hofstra Northwell School of Medicine; the Division of Psychiatry, University College London; Laboratorio Interdisciplinar de Neurociencia Clinica, Universidade Federal de São Paulo, São Paulo; the Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; the University of Melbourne and St. Vincent's Hospital, Sydney; the Department of Psychiatry and Behavioral Sciences, New York Medical College, New York; the Department of Psychiatry, Tel Aviv University, Tel Aviv; the Division of Health Sciences, School of Psychology and Mental Health, Faculty of Biology, Medicine, and Health, University of Manchester, and the Manchester Academic Health Science Centre, Manchester Mental Health and Social Care NHS Trust, Manchester; the Department of Psychiatry, University of Alberta, Edmonton; the Center for Neuropsychiatric Schizophrenia Research and the Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Mental Health Center Glostrup, University of Copenhagen, Copenhagen; the Department of Psychiatry, University of São Paulo Medical School, São Paulo; the Department of Psychiatry, University of Munich, Munich; the Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Programa de Esquizofrenia and Laboratorio Interdisciplinar de Neurociencia Clinica, Universidade Federal de São Paulo, São Paulo; the National Psychosis Service, South London and Maudsley NHS Foundation Trust; the Neuroscience and Behavior Department, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo; the Department of Psychiatry, University of British Columbia; Lundbeck LLC, Deerfield, Ill.; University Department of Psychiatry, Royal Edinburgh Hospital, Edinburgh; the Department of General Psychiatry, Institute of Mental Health, Singapore; the Deparment of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg; the Brain and Mind Centre, University of Sydney, Sydney; the School of Pharmacy, University of Auckland, Auckland, New Zealand; the Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago; the Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich; the Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo; the Department of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne, and Melbourne Health, Victoria; the Schizophrenia Division, Centre for Addiction and Mental Health, Toronto; the Centre for Mental Health, Swinburne University, the Monash Alfred Psychiatry Research Centre, and the Department of Psychiatry, St. Vincent's Hospital Melbourne, Sydney; the School of Pharmacy, University of Otago, Otago, New Zealand; COS and Associates Ltd., Hong Kong; the Department of Neuropsychiatry, Keio University School of Medicine, Keio, Japan; the Department of Neuroscience, University Medical Center Utrecht, Utrecht, the Netherlands; Swinburne University and Monash Alfred Psychiatry Research Centre, Brain and Psychological Sciences Research Centre, Melbourne; the Istanbul Faculty of Medicine, Istanbul University, Istanbul; Clinical Research and Early Development, F. Hoffmann -La Roche Ltd., Basel, Switzerland; the Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, and the MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff; Psychiatry Research, Zucker Hillside Hospital, Long Island Jewish Medical Center, Hofstra Northwell School of Medicine, and the Feinstein Institute for Medical Research, New York.

View Article

Download full-text PDF

Source
http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2016.16
Publisher Site
http://dx.doi.org/10.1176/appi.ajp.2016.16050503DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231547PMC
March 2017

Declining transition rates to psychosis: the role of diagnostic spectra and symptom overlaps in individuals with attenuated psychosis syndrome.

Schizophr Res 2014 Nov 26;159(2-3):292-8. Epub 2014 Sep 26.

Department of Psychiatry and Psychotherapy (UPK), University of Basel, Basel 4056, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2014.09.016DOI Listing
November 2014

Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target.

Neuropharmacology 2013 Jan 23;64:337-46. Epub 2012 Aug 23.

Building 74, Room 3W.209 F. Hoffmann-La Roche AG, DTA CNS, Pharma Research & Early Development, Grenzacherstrasse 124, CH4070 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2012.08.001DOI Listing
January 2013

Cognitive functioning in at-risk mental states for psychosis and 2-year clinical outcome.

Schizophr Res 2012 Dec 29;142(1-3):108-15. Epub 2012 Sep 29.

Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, 4101 Bruderholz, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2012.09.004DOI Listing
December 2012

Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.

Schizophr Bull 2012 Sep;38(5):958-66

Department of Psychiatry, Nathan Kline Institute for Psychiatric Research/Columbia University College of Physicians and Surgeons, Orangeburg, NY 10962, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbs069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446214PMC
September 2012

The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

Schizophr Bull 2011 Nov 21;37(6):1209-17. Epub 2010 Apr 21.

Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbq038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196938PMC
November 2011

Ultra high-risk state for psychosis and non-transition: a systematic review.

Schizophr Res 2011 Oct 23;132(1):8-17. Epub 2011 Jul 23.

University Hospital of Psychiatry, University of Bern, 3010 Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2011.07.002DOI Listing
October 2011

Translating glutamate: from pathophysiology to treatment.

Sci Transl Med 2011 Sep;3(102):102mr2

Translational Schizophrenia Research Center, Nathan Kline Institute/Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3002804DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273336PMC
September 2011

Primary care and the early phases of schizophrenia in the Czech Republic.

Epidemiol Psichiatr Soc 2010 Jul-Sep;19(3):243-50

Charles University School of Medicine, Hradec Kràlové, Czech Republic.

View Article

Download full-text PDF

Source
April 2011

High remission rates from an initial ultra-high risk state for psychosis.

Schizophr Res 2010 Feb 24;116(2-3):168-72. Epub 2009 Oct 24.

Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, 4101 Bruderholz, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2009.10.001DOI Listing
February 2010

The International Study on General Practitioners and Early Psychosis (IGPS).

Schizophr Res 2009 Mar 16;108(1-3):182-90. Epub 2008 Dec 16.

Specialised Early Psychosis Outpatient Clinic for Adolescents and Young Adults, Psychiatric Outpatient Services Bruderholz, Bruderholz, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2008.11.004DOI Listing
March 2009

Subclinical hallucinations in adolescent outpatients: an outcome study.

Schizophr Res 2009 Mar 22;108(1-3):265-71. Epub 2009 Jan 22.

Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, 4101 Bruderholz, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2008.12.018DOI Listing
March 2009

Early auditory sensory processing deficits in mouse mutants with reduced NMDA receptor function.

Neuropsychopharmacology 2008 Jun 22;33(7):1680-9. Epub 2007 Aug 22.

Department of Neuroanatomy, Institute of Anatomy, University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.npp.1301536DOI Listing
June 2008

[On the front line: survey on shared responsibility. General practitioners and schizophrenia].

Sante Ment Que 2007 ;32(1):281-97

CHU Caen, Centre de Recherche Fernand Seguin, Hopital Sacré-Coeur de Montréal, Département de psychiatrie.

View Article

Download full-text PDF

Source
April 2008

Cognitive functioning in the schizophrenia prodrome.

Schizophr Bull 2007 May 4;33(3):761-71. Epub 2007 Apr 4.

Department of Psychiatry, Specialized Outpatient Service for Early Psychosis, Psychiatric Outpatient Services, 4104 Bruderholz, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbm018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526133PMC
May 2007

Developing services for the early detection of psychosis: a critical consideration of the current state of the art.

Eur Child Adolesc Psychiatry 2007 Mar 8;16(2):96-103. Epub 2006 Sep 8.

Specialized Outpatient Clinic for Early Psychosis, Psychiatric Outpatient Services, Department of Psychiatry, 4101 Bruderholz, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00787-006-0579-7DOI Listing
March 2007

Help-seeking pathways in early psychosis.

Soc Psychiatry Psychiatr Epidemiol 2006 Dec 11;41(12):967-74. Epub 2006 Oct 11.

Psychiatric Outpatient Services, University of Bern, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00127-006-0117-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1764202PMC
December 2006

Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia.

Biol Psychiatry 2006 Apr 21;59(8):762-72. Epub 2006 Feb 21.

Exploratory Clinical Development, Translational Medicine, Novartis Pharma AG, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopsych.2005.08.030DOI Listing
April 2006

Defining subjects at risk for psychosis: a comparison of two approaches.

Schizophr Res 2006 Jan 16;81(1):83-90. Epub 2005 Nov 16.

Specialized Outpatient Clinic for Early Psychosis, Psychiatric Outpatient Services, Department of Psychiatry, 4101 Bruderholz, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2005.10.006DOI Listing
January 2006

Mismatch negativity in schizophrenia: a meta-analysis.

Schizophr Res 2005 Jul 23;76(1):1-23. Epub 2005 Jan 23.

University of Zurich, Department of Psychiatric Research, Psychiatric University Hospital Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2004.12.002DOI Listing
July 2005

Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans.

Brain Res 2004 Sep;1019(1-2):189-200

Division of Psychiatry Research, Psychiatric University Hospital Zurich, University of Zurich, Lenggstrasse 31, 8029 Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brainres.2004.05.097DOI Listing
September 2004

How specific are deficits in mismatch negativity generation to schizophrenia?

Biol Psychiatry 2003 Jun;53(12):1120-31

Department of Psychiatric Research, University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
June 2003

Atypical antipsychotics in the treatment of schizophrenia.

Swiss Med Wkly 2003 Feb;133(5-6):63-76

Psychiatric University Hospital Zurich, Heliosstrasse 32, Postfach 31, CH-8029 Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/2003/05/smw-10003DOI Listing
February 2003

Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia.

J Clin Psychiatry 2002 May;63(5):420-4

Department of Psychiatric Research, Psychiatric University Hospital, Zurich, Switzerland.

View Article

Download full-text PDF

Source
May 2002

Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.

Biol Psychiatry 2002 Mar;51(5):400-6

Psychiatric University Hospital Zurich, Department of Psychiatric Research, Zurich, Switzerland.

View Article

Download full-text PDF

Source
March 2002

Effects of risperidone on auditory event-related potentials in schizophrenia.

Int J Neuropsychopharmacol 1999 Dec;2(4):299-304

Research Department, Psychiatric University Hospital, 8029 Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1461145799001595DOI Listing
December 1999